These findings, in line with several recent studies reporting the protective effects of statins in various kidney diseases [42–45], underscore the critical role of lipid metabolic dysregulation in CaOx-induced renal injury and suggest that pharmacological modulation of lipid metabolism may serve as a complementary strategy to targeting the PRMT1/UBE2m axis. Here, PRMT1 is linked to kidney disorder.